Former Klick Health Senior Vice President of Activation Strategy, Silvia De Carvalho, moves to front AXON’s clinical studies practice globally as clinical studies lead. She brings almost two decades of healthcare marketing expertise.
De Carvalho started her career working with the clinical development teams at Sanofi to identify optimal protocols and product viability in the diabetes landscape.
“Silvia is a wonderful addition to the AXON team, not only bringing a strong strategic mind to our client business, but also a high level of ambition for what we can achieve,” said Ralph Sutton, international managing partner of AXON, and its parent company AVENIR GLOBAL.
De Carvalho will help shape how AXON will support patients, caregivers, healthcare professionals, and broader stakeholders navigate the healthcare industry.
“Building on a great foundation, I am excited to continue our growth journey alongside our clients. A first key area of focus for us will be an expansion on our digital engagement services and how we can help clients optimally recruit and engage patients and healthcare professionals within digital and decentralized trials, but also effectively embrace adaptive trial design. The second area of focus will be helping clients to reach diverse patient populations to reflect the communities who may benefit from their medicines," said De Carvalho.
AXON HIRES SILVIA DE CARVALHO AS NEW CLINICAL STUDIES LEAD. (2023, July 17). AXON.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.